SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
South Africa Health Reform: Navigating Innovations and Challenges for 2026
South Africa Health Reform: Contrasts in 2026 Public Health Agenda
South Africa health reform defines the 2026 public health landscape as a mix of breakthroughs like HIV prevention injections and AI-driven TB diagnos...
Advancements in Uncertainty-Aware Diagnostics with ConfiDx LLM
ConfiDx Ushers in Uncertainty-Aware Diagnostics
Uncertainty-aware diagnostics are transforming clinical decision-making through ConfiDx, a large language model (LLM) trained to recognize diagnostic uncertainty in cases with limited cl...
Enhancing Early-Stage Cancer Treatment: Overcoming Barriers for Better Outcomes
Unlocking Early-Stage Cancer Treatment Gains
Early-stage cancer treatment offers significant clinical, humanistic, and economic advantages through timely detection and intervention, yet faces barriers like screening disparities, recurren...